Maleas Grigorios, Mageed Mahmoud
Tierklinik in Lüsche GmbH, Bakum, Germany.
Front Vet Sci. 2021 Jun 18;8:678453. doi: 10.3389/fvets.2021.678453. eCollection 2021.
This retrospective study aimed to evaluate the clinical effect of bone marrow aspirate concentrate (BMAC) and leukocyte rich PRP (LR-PRP) compared to horses undergoing controlled exercise alone in horses with >3 months proximal suspensory desmopathy in hindlimbs (HPSD). Nighty-three horses were divided into three groups according to the treatment: a control ( = 22), LR-PRP ( = 46), and BMAC ( = 25) group. Lameness and ultrasound scores were recorded before treatment (T0) and at 6 months (T1) post-treatment. Records horses considered sound at evaluation and level of performance were additionally registered at 12 months (T2) and 18 months (T3) after treatment. The BMAC cytology profiles from 22 horses were also analysed and compared to clinical outcomes. The results at T1 showed that 9% (2/22) of the horses in the control group were sound compared to 59% (25/46) and 84% (21/25) in the LR-PRP and BMAC groups, respectively. Additionally, ultrasound scores at T1 in the BMAC and LR-PRP groups were improved in comparison with the control group ( = 0.02). At T2, 68% of the horses in the BMAC group and 39% of the horses in the LR-PRP group had returned to the previous performance level. At T3, a significantly higher percentage of horses in the LR-PRP (43%) and BMAC (72%) group were sound when compared to the control (4.6%) group ( = 0.02). Similarly, at T3, significantly more horses of the BMAC (16/25) and of the LR-PRP (15/46) group had returned to the previous or a higher performance level compared to the control (1/22) group ( = 0.01). No correlation was found between long-term clinical outcome and cytology profiles in the BMAC group. In conclusion, long-term outcomes of treatment with LR-PRP or BMAC are significantly better than conventional treatment of the hindlimb chronic PSD in horses. Additionally, BMAC yielded better lameness scores than LR-PRP at short- and long-term follow-up.
这项回顾性研究旨在评估骨髓抽吸浓缩物（BMAC）和富白细胞血小板血浆（LR-PRP）与仅进行控制性运动的马匹相比，对后肢近端悬韧带病变（HPSD）超过3个月的马匹的临床效果。93匹马根据治疗方法分为三组：对照组（n = 22）、LR-PRP组（n = 46）和BMAC组（n = 25）。在治疗前（T0）和治疗后6个月（T1）记录跛行和超声评分。对评估时被认为健康且运动水平的马匹记录在治疗后12个月（T2）和18个月（T3）的情况。还分析了22匹马的BMAC细胞学特征并与临床结果进行比较。T1时的结果显示，对照组9%（2/22）的马匹健康，而LR-PRP组和BMAC组分别为59%（25/46）和84%（21/25）。此外，BMAC组和LR-PRP组T1时的超声评分与对照组相比有所改善（P = 0.02）。T2时，BMAC组68%的马匹和LR-PRP组39%的马匹恢复到之前的运动水平。T3时，与对照组（4.6%）相比，LR-PRP组（43%）和BMAC组（72%）健康马匹的百分比显著更高（P = 0.02）。同样，T3时，与对照组（1/22）相比，BMAC组（16/25）和LR-PRP组（15/46）恢复到之前或更高运动水平的马匹显著更多（P = 0.01）。BMAC组的长期临床结果与细胞学特征之间未发现相关性。总之，LR-PRP或BMAC治疗的长期结果明显优于马匹后肢慢性PSD的传统治疗。此外，在短期和长期随访中，BMAC产生的跛行评分优于LR-PRP。
